NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
26 trialsNCT06980545 2025-05-20
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Assiut University
Phase 3 Not yet recruiting
NCT06916117 2025-04-08
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
RenJi Hospital
Phase 2 Not yet recruiting
NCT05179447 2025-04-01
PROBEAT
Women's Hospital School Of Medicine Zhejiang University
Phase NA Recruiting
NCT06878222 2025-04-01
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Obstetrics & Gynecology Hospital of Fudan University
Phase 2 Recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT06752135 2024-12-30
HRCC1
Azienda Policlinico Umberto I
Terminated
NCT06714084 2024-12-03
CNCMT
Hubei Cancer Hospital
Phase NA Enrolling by invitation
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT06304922 2024-03-12
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
Assiut University
Not yet recruiting
NCT06223763 2024-01-25
SUROVA
Clinica Universidad de Navarra, Universidad de Navarra
Unknown
NCT05173272 2023-12-27
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Sichuan Cancer Hospital and Research Institute
Phase 3 Recruiting
NCT02249013 2021-03-18
Short-course HIPEC in Advanced Epithelial Ovarian Cancer
Professor Fernando Figueira Integral Medicine Institute
Phase 2 Completed
NCT01519869 2020-12-14
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
University of Kentucky
Phase 2 Completed
NCT01461850 2020-10-14
SCORPION
Catholic University of the Sacred Heart
Phase 3 Completed
NCT04515602 2020-08-27
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Shanghai Gynecologic Oncology Group
Phase 3 Not yet recruiting
NCT04370925 2020-06-16
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Recruiting
NCT00662233 2018-10-09
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03180177 2018-01-24
EHNPCTASEOC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT03179579 2017-06-07
Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT00039338 2016-12-05
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT00190528 2016-09-22
A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer
Japan Clinical Oncology Group
Phase 3 Terminated
NCT00112086 2016-08-31
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206
Japan Clinical Oncology Group
Phase 2 Completed
NCT02471027 2015-06-12
The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer
Capital Medical University
Unknown
NCT00462397 2013-08-26
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00075712 2013-08-12
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed